Cell Therapeutics gets a lift as Novartis deals are terminated

For years, Cell Therapeutics CEO Jim Bianco has boasted about the company's long-standing relationship with Novartis. But as of this morning, the relationship is history. The Seattle-based biotech says that it has reacquired the rights Novartis ($NVS) gained on Pixuvri (pixantrone) and Opaxio. The biotech ($CTIC) has agreed to pay out certain milestones on the programs. The company's shares are up 9% this morning. Release

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.